Novo Nordisk A/S - Share repurchase programme

May 17, 2010 08:44 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

For release content, please refer to the attachment.

Attachments

Company Announcement no 26 2010

Company Announcement no 26 2010...

Recommended Reading

April 23, 2026 05:10 ET | Source: Novo Nordisk A/S

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need
Read More
April 20, 2026 08:32 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Read More